Instil Bio TIL 深 滬
已收盤 10-31 16:00:00 美东时间
17.64
+0.480
+2.80%
華盛通- 最 高18.13
- 今 開17.43
- 成交量 5.88万股
- 最 低 16.8061
- 昨 收 17.16
- 總市值 1.15亿
- 52周最高 42.79
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 10.80
- 委 比 98.68%
- 總股本 650.40万
- 歷史最高 589.80
- 量 比 1.14
- 振 幅 7.72%
- 歷史最低 0.80
- 每 手 1
- 風險率 5.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多总统见证，塔吉克斯坦首家现代化建材工厂SUNTILES全线投产
10月20日，塔吉克斯坦首都杜尚别，一场意义非凡的投产仪式隆重举行。由科达制造承建的塔吉克斯坦首家现代化建材整厂项目——SUNTILES 工业园正式建成投产，塔...
10-29 18:34
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
Tiziana Life Sciences will present at BIO-Europe 2025, showcasing its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The event, held in Vienna from November 3-5, 2025, will allow Tiziana to engage with industry leaders and investors. The Company's presentation will focus on its innovative nasal delivery platform and the potential of intranasal foralumab to address neuroinflammatory and neurodegenerative diseases...
10-29 11:00
宜明昂科-B(01541)：IMM2510联合IMM01的IB/II期临床试验完成首例患者给药
宜明昂科-B(01541)发布公告，IMM2510联合IMM01治疗晚期实体瘤的IB/II期临床试验顺利完成首例患者给药，标志着本集团在创新癌症免疫治疗领域取得...
10-23 16:51
天风证券：维持基石药业-B“买入”评级 三抗在ESMO展示出良好的疗效及安全性信号
天风证券发布研报称，维持基石药业-B（02616）“买入”评级，认为CS2009（PD-1/VEGF/CTLA-4三抗）在ESMO展示出初步的有效性数据及良...
10-22 17:27
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
Tiziana Life Sciences, a biotechnology company, has been invited to attend the J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025 in Riyadh, Saudi Arabia. The event aims to bridge cutting-edge research with market solutions, fostering collaboration and investment in the life sciences sector. Tiziana plans to showcase its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody under clinical development...
09-30 12:30
君实生物控股子公司君拓生物向北京沙砾增资8000万元
君实生物（01877）公布，公司控股子公司上海君拓生物医药科技有限公司（以下简称“君拓生物”）及其他投资方拟与北京沙砾生物医药股份有限公司（以下简称“北京沙砾...
09-30 08:43
Motilal Oswal Subsidiary Acquires Stake in Kusumgar Limited
Motilal Oswal Financial Services Limited ( ($IN:MOTILALOFS) ) has issued an upd...
09-24 22:55
Nanobiotix Presents Data Showing A Favorable Safety Profile And Early Efficacy Signals In A Heavily Pre-Treated Population Whose Cancer Progressed After Multiple Prior Lines Of Therapy Including Anti-PD-1; Reports 47.4% ORR And 14.6-Month mOS In Phase 1 Study Of JNJ-1900
Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D)
09-18 04:19
